iBio, Inc. announced that the company and Caliber Biotherapeutics have designated a proprietary fusion protein for cancer treatment as the first product target for advancement on the iBioLaunch platform under the License and Collaboration Agreement between the company and Caliber dated February 14, 2013. Under the terms of the agreement between iBio and Caliber, iBio will receive license and milestone fees for development of product targets. Caliber is responsible for funding clinical development and commercialization of such collaboration products, and iBio is entitled to receive royalties on such product sales and other revenues.